In a J Clin Endocrinol Metab randomized trial, We found no evidence that SGTF was associated with differences in adolescent brain morphology, and no effect of levothyroxine supplementation. Key reported results included There were no significant differences in global brain volumetric measures...
In a J Clin Endocrinol Metab randomized trial, A higher cumulative HbA1c was significantly associated with a higher risk of retinopathy. Key reported results included No significant difference was found in the cumulative incidence of clinically diagnosed DR between the original intervention (N =...
In a J Clin Endocrinol Metab randomized trial, In older men with obesity and hypogonadism, adding TRT for 6 months to LT does not result in further improved cardiometabolic profiles and could potentially blunt some of the metabolic benefits induced by LT. Key reported results included HbA1c...
Adding topiramate to metformin improved 6-month weight loss in women with PCOS, but the benefit was modest and paresthesia was more common.
In SURPASS-PEDS, weekly tirzepatide lowered HbA1c by 2.28 points versus placebo at 30 weeks and also reduced BMI in youth-onset type 2 diabetes.
ATTAIN-1 found that oral orforglipron 36 mg reduced body weight by 11.2% versus 2.1% with placebo over 72 weeks in adults with obesity without diabetes.
In CHIRACIC, adrenalectomy improved home-blood-pressure normotension with less medication versus conservative management in unilateral mild autonomous cortisol secretion-associated hypertension.
In ACROINNOVA 1, monthly self-injected CAM2029 maintained IGF-1 control in 72.2% of adults with controlled acromegaly versus 37.5% on placebo withdrawal.
In STEP UP, semaglutide 7.2 mg reduced body weight by 18.7% versus 3.9% with placebo and outperformed semaglutide 2.4 mg in adults with obesity without diabetes.
In an open-label Graves disease RCT, methotrexate 10 mg weekly added to methimazole increased treatment withdrawal at 18 months, but remains investigational.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
